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Abstract: Platelet cryopreservation has been investigated for several decades as an alternative to 
room temperature storage of platelet concentrates. The use of dimethylsulfoxide as a cryoprotectant 
has improved platelet storage and cryopreserved concentrates can be kept at −80 °C for two years. 
Cryopreserved platelets can serve as emergency backup to support stock crises or to disburden 
difficult logistic areas like rural or military regions. Cryopreservation significantly influences 
platelet morphology, decreases platelet activation and severely abrogates platelet aggregation. 
Recent data indicate that cryopreserved platelets have a procoagulant phenotype because thrombin 
and fibrin formation kicks in earlier compared to room temperature stored platelets. This happens 
both in static and hydrodynamic conditions. In a clinical setting, low 1-h post transfusion recoveries 
of cryopreserved platelets represent fast clearance from circulation which may be explained by 
changes to the platelet GPIbα receptor. Cryopreservation splits the concentrate in two platelet 
subpopulations depending on GPIbα expression levels. Further research is needed to unravel its 
physiological importance. Proving clinical efficacy of cryopreserved platelets is difficult because of 
the heterogeneity of indications and the ambiguity of outcome measures. The procoagulant 
character of cryopreserved platelets has increased interest for use in trauma stressing the need for 
double-blinded randomized clinical trials in actively bleeding patients. 
Keywords: platelets; transfusion; storage; cryopreservation 
 
1. Introduction 
Transfusion of platelet concentrates (PC) is a life-saving intervention for patients suffering from 
acute blood loss but is more often used as a supportive prophylactic therapy for patients with diverse 
hematologic diseases. The demand for PC has increased over the past years. This is caused by a 
growing number of elderly patients who suffer from (chronic) hematologic malignancies like myeloid 
leukemias and non-Hodgkin lymphomas [1]. 
PC are stored at room temperature (RT, 22 °C) with constant agitation. This storage temperature 
was shown to yield superior platelet recoveries after transfusion compared to cold storage (4 °C) [2]. 
However, RT storage severely limits PC shelf-life to maximally 7 days. The exact shelf-life depends 
on the regulation by country. The short shelf-life is a precautionary measure that minimizes the 
chance for bacterial bloom. In addition, ex vivo platelet storage induces a series of biochemical and 
functional changes to the platelet, collectively called platelet storage lesion [3]. This phenomenon 
causes gradual platelet dysfunction and eventually cell death rendering the PC of poor quality after 
longer term RT storage. Efficient PC stock management is therefore highly challenging and this is 
bound to worsen by increasing demands, increasing operational activities (like pathogen 
inactivation) [4] and/or increasing tests for transmittable diseases. Although challenging, PC banking 
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is still manageable in highly structured, densely populated and well-organized regions but becomes 
increasingly problematic when logistics are hampered by vast distances, harsh terrain, lack of 
facilities and/or warfare. 
Alternatives for RT storage have been investigated since the 1970s mainly to improve PC supply 
to the battlefield. Both cold storage (4 °C) and cryopreservation (−96 °C to −180 °C) have been studied. 
The current review will focus on platelet cryopreservation. For reviews on cold storage we refer to 
published work [5–7]. In the mid-seventies, Valeri et al. developed a cryopreservation protocol using 
6% (v/v) dimethylsulfoxide (DMSO) as cryoprotectant and storage at −80 °C without controlled-rate 
freezing [8]. The in vivo platelet recoveries and platelet survival were acceptable in healthy 
volunteers with aspirin-induced thrombocytopathy [8]. To limit toxicity, DMSO had to be removed 
by centrifugation and washing before platelet transfusion. These additional manipulations resulted 
in significant practical limitations of the protocol, especially for use in the military where fast supply 
and thus minimal product manipulation is required. Research into cryopreservation continued but 
focused on its potential use in patientsrefractory to platelet transfusions instead of for military 
purposes. 
The publication of a no-wash protocol by Valeri et al. in 2005 presented a gold standard 
cryopreservation protocol [9,10] and boosted the research field. The method hyperconcentrates the 
platelets by centrifugation after the addition of 6% (v/v) DMSO. This way the platelet-free supernatant 
can be removed prior to freezing resulting in the effective removal of a large fraction of DMSO 
beforehand. After cryopreservation, the hyperconcentrated platelet pellet is reconstituted in either 
plasma or saline. Since this landmark publication, interest in cryopreservation is renewed especially 
in the military or in vast rural areas although the technique may equally function to support regular 
blood banks to further reduce risks of stock failure [10]. 
Despite substantial research into platelet cryopreservation, lots of questions remain. This review 
will summarize the biochemical and molecular changes in platelets following cryopreservation and 
will link these data to results obtained in clinical trials. In doing so we wish to reveal the gaps in the 
research and stimulate further development in this field. 
2. Biochemical Changes to Platelets Following Cryopreservation 
2.1. At. the Level of Single Platelets 
2.1.1. Platelet Viability and Recovery 
Viable nucleated cells bear an intact nucleus with cellular chromatin. The chromatin is not 
detectable using live/dead staining with dyes such as propidium iodide, 7-aminoactinomycin D (7-
AAD) or trypan blue. Loss of membrane integrity in dying or dead cells allows entry of the dye inside 
the cell and this stains the chromatin and marks the cell as non-viable. Platelets are anucleate and 
lack chromatin so they do not divide nor differentiate. Therefore, viability staining in platelets is 
questionable. As an alternative to chromatin live/dead staining acetoxymethylesters of calcein and 
related fluorophores can be used to selectively label platelets that contain active esterases [11]. It 
remains however to be demonstrated what a positive calcein stain then actually means and whether 
this “viable” tag implies that the platelet is functional. Other methods that have assessed “viability” 
in the context of cryopreservation research are extracellular lactate dehydrogenase activity [12], 
hypotonic stress response [13,14] and mitochondrial membrane potential [11,15] but there is no 
evidence that these are more appropriate than calcein staining for the “viability” outcome parameter. 
An alternative parameter often tested in cryopreservation is platelet recovery. This represents 
the number of platelets in the product after cryopreservation relative to that before. Because platelet 
morphology is significantly affected by cryopreservation, recovery is dependent on how a platelet is 
defined. A more appropriate definition therefore is the number of recovered particles with a size and 
shape similar to platelets relative to the number of platelets before. Recovery is largely influenced by 
platelet losses during handling as part of the cryopreservation and reconstitution method. Our data 
demonstrate that approximately 12.5% (±2.1) (mean ± SD, n = 12) of the platelets are lost in the 
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supernatant during the hyperconcentration step of the no-wash protocol published by Valeri et al. 
[10]. Consequently, caution is needed when interpreting published in vitro platelet recoveries 
because these reflect the method’s efficiency and not platelet quality. 
2.1.2. Platelet Morphology 
Platelet morphology is significantly affected during cryopreservation. Most studies indicate an 
increase in mean platelet volume measured by a hematology analyzer [16,17]. Electron microscopy 
images, however, do not suggest an actual increase in platelet size but clearly demonstrate changes 
in platelet shape instead. RT stored platelets have a typical disc shape while cryopreserved platelets 
appear more spherical or balloon-shaped [18,19]. 
Many cryopreserved platelets moreover have morphologic features reminiscent of activated 
platelets. This includes an irregular ruffled cell surface and an increased number of pseudopodia 
(Figure 1). A minority of cryopreserved platelets displays a condensed morphology marked by 
cytoplasmic membrane disintegration [12,14,18,19]. These shape changes reduce the archetypical 
anisotropic morphology of RT stored platelets that results in the strong diffraction of light and that 
is often used as a quality outcome parameter in blood banks called “swirl” [20]. Consequently, 
cryopreserved platelets have significantly less or even no swirl compared to RT stored platelets [21]. 
 
Figure 1. Morphologic and biochemical changes to platelets after cryopreservation. The model 
indicates known morphologic and biochemical changes to platelets going from (A) resting, healthy 
cells before cryopreservation to (B) altered phenotype after cryopreservation. Morphologic alterations 
induced by cryopreservation include a significant shape change from discoid to spherical platelets 
and increased numbers of platelet pseudopodia. Main changes to the cytoplasmatic membrane are 
increased permeability, extracellular vesicle formation and phosphatidylserine flop from the inner to 
the outer part of the bilayer. The latter two catalyze fibrin formation by providing a binding surface 
for the tenase and prothrombinase coagulation factor complexes. Many platelet surface receptors are 
expressed differently after cryopreservation. P-selectin expression is increased, GPIbα expression is 
decreased and the integrin αIIbβ3 is (in part) activated each marking events of granule content release, 
receptor ectodomain shedding and fibrinogen binding, respectively. Finally, metabolic changes are 
detected by defective mitochondrial function. 
2.1.3. Changes to the Cytoplasmic Membrane 
Cryopreservation causes a significant increase in extracellular vesicle (EV) content (synonyms: 
microparticles, microvesicles or exosomes) in PC. These EV have variable diameters ranging from 20 
to 200 nm. The EV population is characterized by the expression of high levels of the 
aminophospholipids phosphatidylethanolamine (PE) and -serine (PS) [16,19]. Exact enumeration of 
EV in PC is difficult because of the detection limit on particle size in typical flow cytometers and 
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because definitions of platelet EV are ambiguous. However, in general, EV content increases 
approximately fivefold after cryopreservation [14,17–19]. 
PS/PE expression is not limited to the EV population but applies to normally sized 
cryopreserved platelets as well. In resting RT stored platelets, PS/PE is actively kept on the inner 
leaflet of the cytoplasmic membrane (Figure 1). The aminophospholipids however flop to the outer 
membrane during platelet activation and/or platelet apoptosis. This loss of membrane asymmetry 
can be detected in a Ca2+-dependent manner by fluorescently labeled Annexin V or lactadherin using 
flow cytometry [16,17,19,22]. 
Next to loss of membrane asymmetry, membrane integrity of platelets is also affected during 
cryopreservation. In an experiment using platelets that were preloaded with fluorescein, 40% of the 
cytoplasmic dye was released in the supernatant following cryopreservation with 5% (v/v) DMSO 
[23]. This was twofold less than in conditions without cryoprotectant but nonetheless indicates 
significant damage to membrane integrity. In addition, the loss of platelet molecules by freezing is 
substantially addressed in studies on human platelet lysate which is prepared exactly by (repeated) 
freeze-thawing [24,25]. It therefore seems worthwhile investigating if other molecules are lost from 
cytoplasma during cryopreservation. Of note, the release of cytoplasmic molecules should not be 
confused with granule release which is a form of controlled exocytosis and is not related to membrane 
damage. 
2.1.4. Surface Receptor Expression 
P-selectin (CD62P) is a receptor residing inside the resting platelet on membranes of α-granules. 
During platelet activation, the α-granules fuse with the cytoplasmic membrane releasing its content 
in the surrounding medium in a process called degranulation. This causes integration of P-selectin in 
the cytoplasmic membrane and exposes the receptor to the platelet exterior (Figure 1). 
Cryopreservation results in a significant increase of P-selectin expression on the platelet surface 
implying that cryopreservation causes spontaneous degranulation [11,12,18,19,23,26,27]. This may 
not necessarily be the same as platelet activation in this case because integrin αIIbβ3 activation is not 
substantially increased after cryopreservation. Using PAC-1 in flow cytometry to specifically label 
platelets that express activated integrin αIIbβ3, we and others only found a small increase in the fraction 
of platelets expressing activated integrin and no difference in PAC-1 fluorescence after 
cryopreservation [12,15,17,26,28,29]. 
Another platelet specific receptor is the GPIbα portion of the GPIbα/IX/V complex that binds 
von Willebrand factor (VWF) for platelet adhesion during primary hemostasis. Surface receptor 
expression of GPIbα on cryopreserved platelets has been studied extensively over the years with 
some important observations. A significant decrease in GPIbα receptor expression is consistently 
found on cryopreserved platelets using flow cytometry [12,15,17,26,29,30]. This can be explained by 
ectodomain shedding of GPIbα resulting in the release of the extracellular soluble part of the receptor 
called glycocalicin. This glycosylated molecule can be found at low levels in the supernatant of 
regular PC during RT storage. It is also consistently found at low concentrations in plasma from 
healthy donors. Glycocalicin levels are significantly increased in the supernatant of cryopreserved 
platelets [11,17] implying that sheddases are activated by cryopreservation. 
Cold storage (4°C) of platelets may cause GPIbα receptor clustering and deglycosylation of N-
glycans, a phenomenon that leads β-N-acetylglucosamine (β-GlcNAc) exposure and accelerated 
clearance from circulation [31–33]. These characteristic changes to GPIbα hydrocarbon sidechains are 
however not necessarily applicable to cryopreserved platelets because Waters et al. could not find 
significant GPIbα clustering and Zhao et al. found no increased exposure of β-GlcNAc after 
cryopreservation [28,34]. 
When measuring CD42b in cryopreserved platelets using flow cytometry two subpopulations 
can often be distinguished based on fluorescence. One subpopulation has a normal CD42b signal and 
thus normal GPIbα expression and the other has a significantly lowered signal. This phenomenon 
was observed both in human and in baboon cryopreserved platelets. In general, approximately half 
of cryopreserved platelets have low GPIbα expression (GPIbαlow) while the other half has normal 
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GPIbα expression (GPIbαnormal) [11,12,17,26,30]. Specific features and relevance of this phenomenon 
will be discussed in detail in paragraph 3. 
2.1.5. Metabolic Changes 
Both mitochondrial membrane potential and hypotonic shock response were used as 
determinants of platelet metabolism. Both parameters were significantly affected after 
cryopreservation suggesting changes to mitochondria and/or anaerobic respiration. How these 
metabolic changes relate to decreased platelet function or (pro)coagulation and thus thrombus 
formation is not (yet) known [11,14,15,18]. 
pH measurements immediately post-thaw are not relevant as such because they solely and 
entirely dependent on the composition of the solution used for PC reconstitution. At that time point 
platelets do not contribute to pH. It can however be used as a baseline to identify pH changes as a 
function of subsequent storage post-thaw. Longitudinal follow-up of pH is typically performed by 
blood institutions as a quality control for RT stored platelet metabolism. It even serves as a gold 
standard [20]. Because cryopreserved platelets are generally transfused within 4 h after thawing, 
determination of pH during storage is less relevant and studies provide data limited to a 24 h post-
thaw period [9]. The pH of cryopreserved PC did not change in these 24 h post-thaw despite small 
decreases in glucose and increases in lactate content [11,12,14,28]. Direct comparison of glucose 
consumption and lactate production of cryopreserved and RT stored platelets did indicate an 
acceleration of the glycolytic pathway [14]. This could be a result of temperature cycling stress. 
2.1.6. Signal Transduction 
Only one study investigated changes in signal transduction in vitro after cryopreservation of 
platelets. In general, a lower degree of phosphorylation was detected on all investigated proteins 
including Lyn, ERK and Akt after cryopreservation [22]. Phosphorylation of signaling proteins can 
both positively and negatively regulate platelet function and so, an overall lower phosphorylation 
activity may explain certain observations. Unraveling signal transduction pathways after 
cryopreservation is therefore required to better understand what signaling cues are affected in 
platelets during cryopreservation. 
2.2. Platelet function 
2.2.1. Agonist-Induced Integrin Activation and Aggregation 
Platelet aggregation is still considered the clinical gold standard for detecting platelet defects 
[35]. Therefore, when aggregation is significantly, affected platelets are often considered overall 
dysfunctional. Cryopreserved platelets respond poorly in light transmission aggregation when single 
agonists are used at concentrations that typically cause maximal aggregation in RT stored platelets. 
Cryopreserved platelets will generally not respond to weak agonists like adenosine diphosphate 
(ADP) but this is often the case for RT stored platelets as well [36]. 
However, aggregation is detected with strong agonists like thrombin or collagen added at high 
concentrations [22]. Furthermore, when several agonists are combined like thrombin receptor agonist 
peptide 6 (TRAP-6) with ADP and epinephrine substantial aggregation is detected in cryopreserved 
platelets albeit two- to three-fold lower than in RT stored platelets [17,37]. Ristocetin induced 
agglutination requires less outside-in signaling to crosslink platelets via GPIbα and VWF compared 
to agonist induced aggregation which crosslinks platelets via fibrinogen and integrin αIIbβ3. 
Therefore, agglutination of cryopreserved platelets is possible using 1.5 mg/mL ristocetin. The 
amplitude is about 75% that of RT stored platelets [17]. 
These findings are in line with measurements of integrin αIIbβ3 activation using PAC-1 in flow 
cytometry. This outcome measure is significantly decreased after cryopreservation in response to 
single agonists like ADP, collagen, TRAP-6, epinephrine, thrombin or cross-linked collagen-related 
peptides (CRP-XL). It should be noted that the magnitude of the response differs depending on the 
nature of the agonist but decreases between cryopreserved and RT stored controls were apparent in 
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both buffy coat and apheresis-derived PC [12,15,17,22,26]. Both the aggregation and integrin αIIbβ3 
activation assays indicate the requirement for strong platelet stimulation after cryopreservation to 
obtain measurable amplitudes of platelet activation. However, even at high concentrations of strong 
agonists the activation level of cryopreserved platelets is lower than the responses obtained by RT 
stored platelets using the same test conditions. 
2.2.2. Platelet Adhesion and Coagulation in Hydrodynamic Flow 
Adhesion to extracellular matrix proteins (ECM) of cryopreserved platelets in reconstituted 
blood was investigated by two groups using different models, i.e., the Baumgartner model and a real-
time microfluidic flow chamber model, respectively [38–40]. Using the Baumgartner model, Cid et al. 
found 10% surface coverage on denuded rabbit aorta using cryopreserved platelets perfused at a wall 
shear rate of 600 s−1, while surface coverage was 23% for RT stored platelets [41]. We investigated 
platelet adhesion by perfusion of reconstituted whole blood onto collagen only or onto collagen and 
tissue factor (TF) in microfluidic flow chambers at a wall shear rate of 1000 s−1. The adhesion rate of 
cryopreserved platelets was decreased twofold compared to paired platelets before cryopreservation 
[17]. Despite differences in technical set-up, wall shear rate and experimental endpoint, both 
independent experiments show significant impaired platelet adhesion after cryopreservation. 
Both models were also used to assess coagulation in the presence of cryopreserved platelets. 
Fibrin coverage after 4 min of perfusion in the Baumgartner model was not significantly different 
between RT stored and cryopreserved platelets despite the lower number of adhered platelets [41]. 
In our microfluidic system fibrin formation onset was even faster in the presence of cryopreserved 
platelets compared to control non-cryopreserved cells [17]. This implies that adherent cryopreserved 
platelets are more procoagulant than regular platelets because despite the twofold decreased platelet 
coverage, fibrin formation is at least as quick or even quicker. 
2.2.3. Coagulation in Static Conditions 
Coagulation is mostly studied in static conditions, i.e., in the absence of hydrodynamic flow. 
Dynamic measurement of thrombin generation is performed by thrombin generation assays (TGA) 
and fibrin formation can be studied using rotational thromboelastometry (ROTEM). These assays can 
provide information on the (pro)coagulant properties of (cryopreserved) platelets because platelets 
are natural catalysts of coagulation. 
Results from TGA across labs should however be compared with caution. Variables like platelet 
count, anticoagulant concentration, buffer composition and TF concentration are not standardized 
and can have a significant impact on the absolute values obtained by TGA [42]. To make the TGA 
dependent on platelets, a low TF concentration should be used and all other variables should be kept 
constant. When performed as such, cryopreserved and RT stored platelets can both catalyze thrombin 
generation in a platelet dose-dependent manner. However, peak thrombin concentrations are 
twofold higher in the presence of cryopreserved platelets compared to RT stored platelets. 
Furthermore, lag times are significantly shorter in the presence of cryopreserved platelets compared 
to RT stored platelets [17,19]. 
ROTEM is a standardized clinical test that provides dynamic information on the speed of 
coagulation initiation, propagation and on clot strength expressed respectively as clotting time (R-
time), clot formation time (K-time) and maximal amplitude. This assay is particularly dependent on 
fibrinogen concentrations but if fibrinogen levels are kept constant the subtle contribution of platelets 
can be measured as well. Tests in ROTEM confirmed the above mentioned findings in TGA including 
faster clotting time for cryopreserved platelets compared to RT stored platelets. A slight decreased 
maximal amplitude suggests that the clot is less firm in the presence of cryopreserved platelets 
compared to RT stored platelets. Contradictory results are published for clot formation time as some 
groups found a decrease in this parameter after cryopreservation while others found no differences 
between storage conditions. This discrepancy may be explained by the agonist used to perform 
ROTEM, e.g., kaolin, ellagic acid or TF [12,16,17]. 
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In conclusion, the data for coagulation obtained by using hydrodynamic flow, TGA and ROTEM 
all suggest a faster onset of coagulation with higher thrombin production in the presence of 
cryopreserved platelets compared to RT stored platelets. Whether fibrin clot strength differs between 
conditions needs to be investigated in more detail. 
2.2.4. Procoagulant Cryopreserved Platelets 
How can cryopreserved platelets with aberrant morphology, altered surface receptor expression 
levels and decreased agonist responses be able to promote coagulation similar to or even better than 
RT stored platelets? Recently, the text book coagulation cascade has been challenged by a novel 
concept called ‘cell-based coagulation’ [43]. The idea is based on two cell types which are physically 
separated in healthy tissue, i.e., TF-bearing cells in non-vascular compartments and circulating 
platelets devoid of TF. In this model, cell-based coagulation is divided in three separate but 
overlapping phases called initiation, amplification and propagation. Upon injury the leaking blood 
contacts the interstitial TF-bearing cells leading to release of factor IXa and the formation of the 
prothrombinase complex (factor Va/Xa) with subsequent generation of small amounts of thrombin. 
During this initiation phase, platelets adhere to the site of injury onto von Willebrand factor and 
collagen. Amplification follows when adherent platelets sense the small amounts of thrombin via G-
protein coupled protease-activated receptors (PAR) that induce a positive feedback loop in the 
platelet to catalyze factor V, VIII and XI activation on the platelet surface. In the propagation phase 
platelets are strongly activated and their increased surface area provides an assembly stage to scaffold 
prothrombinase and tenase (factor IXa/VIIIa) complexes generating large amounts of (local) thrombin 
[43,44] (Figure 1). 
Cryopreserved platelets possess a pre-activated surface membrane because of the abnormally 
high aminophospholipid (PS and PE) expression, even in the absence of TF-bearing cells or adhesion 
to injured vessel wall proteins. Possibly, PS/PE exposure allows skipping the initiation steps of the 
described cell-based coagulation model. It is known that PS/PE is required to successfully assemble 
the prothrombinase and tenase complexes on platelets. This may explain the apparent procoagulant 
character of cryopreserved platelets. The increased binding of coagulation factors to cryopreserved 
platelets was observed in 1999 by Barnard et al. who demonstrated a 4-fold increased binding of 
factor V compared to RT stored controls [26]. In addition, the contribution of PS was demonstrated 
by Tegegn et al. who showed that thrombin generation in the presence of cryopreserved platelets 
could be significantly decreased in the presence of lactadherin which inhibits assembly of coagulation 
complexes by blocking PS [19]. 
Furthermore, cryopreservation increases the EV content significantly. These EV provide 
additional surface area for coagulation factor/complex adhesion. In addition, platelet-derived EV are 
50- to 100-fold more procoagulant than activated platelets alone [45]. This way EV formation during 
cryopreservation provides not only an increase in surface area but the actual cellular particles may 
be biochemically better suited to catalyze coagulation. This is demonstrated in an elegant experiment 
showing that thrombin can still be generated using platelet-poor, EV-rich supernatant of 
cryopreserved PC albeit at a slower rate than in the presence of cryopreserved platelets [19]. High 
speed centrifugation of the cryopreserved PC to remove both platelets and EV however resulted in 
very little and slow thrombin generation. This suggests that maximal procoagulant effects of 
cryopreservation contain a contribution of both platelets and EV [16,19,29]. 
The impact of cryopreservation on platelet morphology, biochemistry and function is 
summarized in Table 1 in comparison to control RT stored platelets. 
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Table 1. Summary of morphologic and biochemical characteristics and their impact on platelet 
function of RT stored or cryopreserved platelets. 
 RT Stored Platelets Cryopreserved Platelets 
General   
Storage conditions 22°C with constant agitation −80°C without agitation 
Shelf-life 5–7 days At least 2 years 
Platelet Characteristics   
Morphology Disc Sphere 
Cytoplasmic membrane Membrane asymmetry 
PS/PE expression 
Loss of membrane integrity 
Degranulation Minimal Increased 
Metabolism Normal 
Loss of mitochondrial membrane potential 
Decreased hypotonic shock response 
Accelerated glycolysis 
GPIbα shedding Minimal Increased 
EV formation Minimal Increased 
Platelet Function   
PAC-1 binding upon stimulation with 
agonists 
Normal Decreased 
Aggregation response upon 
stimulation with agonists 
Normal Decreased 
Adhesion rate to ECM under flow Normal Decreased 
Coagulation rate under flow Normal Increased 
ROTEM   
     Clotting time Normal Shortened 
     Clot firmness Normal Slightly decreased 
TGA   
     Peak thrombin Normal Increased 
     Lag time Normal Shortened 
2.3. Clinical Relevance 
It is beyond the scope of this review to present a comprehensive overview of all clinical trials 
performed with cryopreserved platelets in the past because excellent work has been published by 
others [46]. We would, however, like to highlight the main findings of recent clinical trials and 
highlight some aspects that still require further investigation. 
2.3.1. Recovery/Count Increment and Survival Time 
Typical outcome parameters for evaluating transfusion success are platelet recovery and 
(corrected) count increment ((C)CI). Platelet recovery is mainly determined in test populations of 
healthy volunteers [8,10,18] while CI is used in patients and is defined as the change in platelet count 
1 or 24 h post-transfusion [27,47,48]. This outcome can be corrected for body surface area, i.e., CCI. In 
most studies cryopreserved platelets are cleared from circulation faster than RT stored platelets. In 
healthy volunteers, a 50% lower recovery is found when compared to transfusion of RT stored 
platelets [10,18]. Furthermore, the (C)CI of cryopreserved platelets is significantly lower in patients 
with hematologic malignancies or in actively bleeding patients when compared to RT stored platelets 
[27,47,48]. The reason for accelerated clearance is not entirely clear, but changes to platelet receptors 
may mark the platelet for clearance as is found for cold stored platelets (4°C) in animal models 
[31,32,49]. Platelet survival was determined in several clinical studies investigating the maximal 
circulation time of platelets post-transfusion. These data were summarized by Slichter et al. and mean 
survival time was 7.4 (± 1.4) days for cryopreserved platelets compared to 8.4 (±0.4) days for RT stored 
platelets which was a significant decrease but still within FDA criteria [46]. 
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2.3.2. Efficacy 
Assessing efficacy of (cryopreserved) transfused platelets is not easy because of several reasons. 
One is the heterogeneity of indications for platelet transfusion ranging from accidental trauma to 
major surgery to hemato-oncologic and inherited or acquired platelet disorders. For each indication, 
uniformity of the patient population is difficult to achieve and not all patients present with (serious) 
bleeding. To sufficiently power clinical studies on bleeding, a large number of patients needs to be 
included. Furthermore, standardized toolboxes are lacking to objectively measure the platelet 
contribution in transfusion efficacy. Instead, outcome measures like blood loss, number of blood 
product transfusions, time between PC transfusion, hemorrhage and cessation of bleeding are most 
commonly used to determine transfusion efficacy. In addition, although cryopreservation protocols 
have become increasingly uniform significant variation remains in DMSO concentration, storage 
temperature (−80 °C vs. −150 °C), freezing rate, resuspension solution (plasma vs. saline) and the type 
of cryopreservation bag used. Foremost, the platelet concentrate itself varies between studies because 
platelet separation methods are different throughout the globe. Resulting variables are platelet 
concentration, platelet additive solution, type of storage bag and pathogen inactivation [37]. 
Because cryopreserved platelets are procoagulant, they seem ideally suited to treat actively 
bleeding patients like in (acute) trauma [33,50–52]. Clinical trials in acute trauma are a practical 
challenge and most published studies are observational [53,54]. This renders a low quality score, e.g., 
by GRADE evaluation [55]. A recent study reported comparison of cryopreserved and RT stored PC 
after transfusion in polytraumatic patients (n = 25 and n = 21, respectively). The data show that despite 
a twofold lower platelet count after transfusion of cryopreserved compared to RT stored platelets (p 
= 0.02) no differences in hematologic outcomes were found [47]. The measured outcomes were 30-
day survival, number of administered blood products, fibrinogen concentrate, tranexamic acid 
administration and adverse events. The recent CLIP-I trial in Australia [56] was a pilot study to 
primarily test feasibility and safety of the protocol. As a secondary outcome they reported increased 
use of fresh frozen plasma and PC in the cryopreservation cohort (n = 23) compared to the RT stored 
cohort (n = 18) [56]. Reasons for differences in outcome between the studies of Bohonek et al. and the 
CLIP-I trial are unknown but could be related to differences in cryopreservation and thawing 
method. 
Assessment of the platelet contribution to transfusion efficacy in non-bleeding 
thrombocytopenic patients is different than in actively bleeding patients because administration is 
prophylactic. In such studies (C)CI is most often the primary outcome although some studies 
measure bleeding time before and after transfusion. Although most studies showed a decreased 
bleeding time upon transfusion with cryopreserved platelets, this was not the case for all studies [46]. 
Finally, a specific cohort of patients is those that suffer from platelet refractoriness. It is believed 
that platelet refractoriness occurs in chronically transfusion dependent patients who raise an immune 
response to multiple donor antigens. Introduction of leukoreduction decreased the incidence of 
platelet refractoriness but still up to 10% of acute leukemia patients are affected by refractoriness 
[27,57]. Currently, transfusion of phenotypically matched PC is the sole solution for patients suffering 
from platelet refractoriness. In 2016, Gerber et al. showed that platelet counts in these patients can be 
increased after transfusion of autologous cryopreserved PC contrary to transfusion of regular ABO-
matched, RT stored PC. This suggest that transfusion of autologous cryopreserved platelets may offer 
a (temporary) solution in cases where phenotypically matched PC are not available [27]. 
2.3.3. Safety 
In early studies safety measures focused on the potential toxicity of DMSO. From the 1970s until 
1990s, cryopreserved PC were extensively washed to reduce DMSO administered to the study 
population. Since the no-wash method high (5–6%) DMSO concentrations are quickly reduced to 400–
600 mg per PC after reconstitution in plasma or saline [10]. Only minor adverse events have been 
directly linked to DMSO administration including metallic taste, sulfuric breath odor and nausea 
[46,58]. 
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Because cryopreserved platelets are procoagulant, concerns for thromboembolic events after 
transfusion were raised. However, so far, neither thromboembolic events nor any other serious 
adverse events were reported in trials designed to study the safety of cryopreserved platelets 
[46,56,58]. 
3. Changes to the GPIbα Receptor 
Cryopreservation modifies GPIbα in platelets resulting in two (often) well separated platelet 
subpopulations in flow cytometry based on CD42b fluorescence intensity. One subpopulation has 
abnormally low CD42b fluorescence designated GPIbαlow and the other has normal CD42b 
fluorescence, GPIbαnormal. The GPIbαlow platelet subpopulation expresses high PS/PE, responds poorly 
to agonists measured by PAC-1 binding and has increased factor V binding. On the contrary PS/PE 
expression is relatively low, PAC-1 binding is high after agonist stimulation and factor V is not as 
high in the GPIbαnormal subpopulation [17,26]. 
The relative fractions of GPIbαlow vs. GPIbαnormal platelet subpopulations in PC differed between 
products prepared by blood institutions in the USA, Australia and Belgium [17]. High GPIbαlow 
content implied low platelet function and vice versa. For instance platelet integrin activation, 
agglutination and platelet adhesion to collagen were significantly lower in PC with a high 
GPIbαlow/GPIbαnormal ratio compared to PC with a low ratio [17]. It is not clear why this is or what 
processes underlie the differences observed between blood institutions. 
To investigate the role of GPIbα subpopulations, we inhibited ectodomain shedding during 
cryopreservation using the matrix metalloproteinase inhibitor marimastat. This hydroxamic acid 
inhibits A Disintegrin And Metalloproteinase 17 (ADAM17) which is the membrane bound enzyme 
that catalyzes GPIbα ectodomain shedding [59]. 
Our data show that marimastat (10 µM) successfully shifted the CD42b fluorescence profile in 
cryopreserved PC from 52% (±2) in the GPIbαnormal subpopulation without inhibitor to 91% (±1) with 
inhibitor (Figure 2A). Western blotting of PC supernatant confirmed that this was a consequence of 
shedding inhibition (Figure 2B). Cryopreservation caused a 2.3-fold increase in glycocalicin levels 
compared to paired samples before freezing. This was completely inhibited in the presence of 10 µM 
marimastat. Despite complete inhibition of GPIbα shedding, cryopreservation in the presence of 
marimastat could however not rescue the phenotype of cryopreserved platelets. Agglutination using 
1.25 mg/mL ristocetin was 32% and 29% (amplitude) in the absence and presence of 10µM 
marimastat, respectively compared to 54% before freezing (Figure 2C). Adhesion rates of 
cryopreserved platelets to collagen in microfluidic flow chambers were significantly lower compared 
to paired samples before cryopreservation (p = 0.03) and this was irrespective of marimastat addition 
(p = 0.98, n = 3) (Figure 2D,E). These data show that GPIbα ectodomain shedding is a consequence of 
platelet cryopreservation and that its inhibition cannot improve platelet function in agglutination and 
adhesion experiments. GPIbα expression levels have also been linked to platelet circulation time, but 
this was not addressed in our study. The effect of shedding inhibition on this parameter thus is not 
known. It may be interesting to investigate this because Barnard et al. showed that the 2-h 
posttransfusion recovery of cryopreserved baboon platelets was 48% and mostly attributed to the 
GPIbαlow subpopulation which was cleared from circulation before 1 h after transfusion, while this 
was not the case for GPIbαnormal subpopulation. In addition, circulation time of the GPIbαnormal 
subpopulation was almost 6 days [26]. The Valeri group compared two cryopreservation protocols 
for human platelets. One protocol caused approximately 20% GPIbαlow platelets and the other 50% 
GPIbαlow platelets and corresponding in vivo recoveries were 35–40% and 25–30%, respectively. No 
differences in circulation time were found [10]. There is currently no direct evidence that the lower 
recovery is a consequence of the presence of the larger GPIbαlow subpopulation but together with the 
data from Barnard et al. we consider it worthwhile investigating. 
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Figure 2. Inhibition of GPIbα shedding during cryopreservation. The effect of cryopreservation in the 
presence or absence of 10µM marimastat was investigated. Comparison was with paired samples 
before cryopreservation. The methods used have been described in detail before [17,37,40]. (A) The 
percentage of GPIbαnormal platelets was determined by CD42b measurements in flow cytometry. (B) 
Glycocalicin levels were determined by western blotting of platelet-free supernatant. (C) The 
agglutination amplitude of the platelets was measured in light transmission aggregometry using 1.25 
mg/mL ristocetin. (D) The platelet surface coverage (%) as a function of time was determined by video 
microscopy of microfluidic flow chambers coated with collagen. Reconstituted whole blood spiked 
with 250,000 fluorescently labeled platelets per µL was perfused at a wall shear rate of 1000 s−1. (E) 
Representative endpoint image of fluorescently labeled adherent platelets after 6 min of perfusion. 
4. Perspectives 
Significant progress has been made in the search for alternative storage methods for platelets 
but important information is still lacking before cryopreserved platelets can be used in routine blood 
banks. The no-wash protocol [10] still uses DMSO as a cryoprotectant and patients receiving multiple 
transfusions may still be exposed to large quantities of this toxic solvent. Alternatives have been 
investigated but none seem superior to DMSO [60]. Apart from the cryoprotectant, a substantial 
number of other variables influences the quality of cryopreserved platelets. In addition, the large 
number of inherent variables that contribute to a successful blood product make comparison between 
clinical studies challenging in anyway. Consequently, future efforts should also go to the selection of 
a standard clearly-defined cryopreservation protocol. This may help to design more reliable clinical 
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trials with outcomes that will be more comparable. Until then, safety and efficacy trials will be 
required in every region where cryopreservation is required. So far, biochemical investigation of 
signal transduction in cryopreserved platelets is very limited. Such studies may be crucial in 
unravelling the pathways that are affected. This understanding may help explain the discrepancy 
between the decreased platelet function in vitro and the encouraging data from clinical trials. It may 
also help to design novel additive solutions that contain molecules to protect affected pathways. 
Finally, next to their established role in hemostasis platelets contribute to many other processes 
including inflammation, (lymph)angiogenesis, cancer and wound healing. Transfusion of 
(cryopreserved) platelets is underinvestigated in these fields and requires special attention from the 
research community in the future. 
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Abbreviations 
7-AAD 7-aminoactinomycin D 
ADAM17 A Disintegrin And Metalloproteinase 17 
ADP Adenosine diphosphate  
β-GlcNAc β-N-acetylglucosamine 
(C)CI (Corrected) count increment 
CRP-XL Collagen-related peptide, cross-linked 
DMSO Dimethylsulfoxide 
ECM Extracellular matrix 
EV Extracellular vesicle 
PAR Protease-activated receptor 
PC Platelet concentrate 
PE Phosphatidyl ethanolamine 
PS Phosphatidyl serine  
ROTEM Rotational thromboelastometry 
RT Room temperature 
TF Tissue factor 
TGA Thrombin generation assay 
TRAP-6 Thrombin receptor agonist peptide-6 
VWF von Willebrand factor 
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